The number of women dying from breast cancer will begin rising for the first time in decades due to unhealthy living, a new report predicts.
By 2022, three decades’ of progress cutting the death toll in Britain will be in reverse, despite improvements in medical science, experts have said.
Breast Cancer Now, which led the new research, said that while modern medicine means an individual woman’s chance of beating cancer is now getting better, more are developing the disease in the first place due to preventable lifestyle factors.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.